Jingrui Liu

发表

Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects

Hong Zhang, Yanhua Ding, Z. Jiao, 2019, Clinical pharmacology in drug development.

S-amlodipine–bisoprolol combination therapy caused elevated transaminases and triglyceride levels in healthy Chinese subjects: a randomized controlled, open-label, multiple-dose pharmacokinetic interaction study

J. Niu, Xiaojiao Li, Hong Zhang, 2019, Expert opinion on drug metabolism & toxicology.

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Frontiers in Pharmacology.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

J. Niu, Xiaojiao Li, Hong Zhang, 2018, The Journal of pharmacy and pharmacology.

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes

Z. Ning, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Inulin-Type Fructans Change the Gut Microbiota and Prevent the Development of Diabetic Nephropathy.

Yan Yang, Ruolan Dong, L. Tu, 2022, Pharmacological research.

Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly

Shiping Ma, Hushan Wang, Xiaojiao Li, 2021, Frontiers in Pharmacology.

Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Expert opinion on investigational drugs.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

Haijing Wei, Yanhua Ding, Binhua Lv, 2020, Frontiers in Pharmacology.

Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo.

Yingjie Guo, J. P. Fawcett, J. Gu, 2015, Molecular pharmaceutics.

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Shiping Ma, Chengluan Xuan, Xiaojiao Li, 2022, Annals of medicine.

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

X. Yang, Xiaojiao Li, Hong Zhang, 2021, Frontiers in Pharmacology.

Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals

J. Niu, Xiaojiao Li, Hong Zhang, 2021, Expert opinion on investigational drugs.

Using Dissolution and Pharmacokinetics Studies of Crystal Form to Optimize the Original Iloperidone

W. Guo, G. Zhu, F. Sun, 2013 .

The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability

Ting Xu, Xiaojiao Li, Hong Zhang, 2022, Expert opinion on investigational drugs.

Randomised clinical trial: safety, efficacy and pharmacokinetics of HS‐10234 versus tenofovir for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Alimentary Pharmacology and Therapeutics.

Tolerability, pharmacokinetics and antiviral activity of rHSA/IFN&agr;2a for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2017, British journal of clinical pharmacology.

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Frontiers in Pharmacology.

Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2019, Antiviral research.

Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-Deficiency Anemia.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Annals of medicine.

A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men

Xiaojiao Li, Hong Zhang, Haijing Wei, 2021, Expert Opinion on Biological Therapy.

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults

Xiaojiao Li, Hong Zhang, Haijing Wei, 2021, Frontiers in Pharmacology.

Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Antiviral research.

Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Expert Opinion on Investigational Drugs.

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Huanming Chen, Hui Lu, J. Niu, 2023, BMC Medicine.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Frontiers in Pharmacology.

Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects

Yingjie Guo, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo.

Yingjie Guo, J. P. Fawcett, J. Gu, 2015, Molecular pharmaceutics.